Cyclosporine immunotherapy

Clinics in Dermatology

Volumn 15, Issue 5, 1997, Pages 811-821

  De Rie, Menno A ^a   Bos, Jan D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ASCOMYCIN; AZATHIOPRINE; CD27 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHILIN; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN A [8 DEXTRO O (2 HYDROXYETHYL)SERINE]; CYTOKINE; DITHRANOL; HLA DR ANTIGEN; HYBRID PROTEIN; IMMUNOPHILIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; OKT 4; PEPTIDE T; PIMECROLIMUS; PSORALEN; RAPAMYCIN; SDZ 281240; TACROLIMUS; TIOGUANINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG INDICATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MICROEMULSION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHOTOCHEMOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; PUVA; REMISSION; REVIEW; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION;

EID: 0030815496     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00012-6     Document Type: Article

References (106)

1. Prens E, Debets R, Hegmans J. T lymphocytes in psoriasis. Clin Dermat 1995;13:115-29.
2. Baker BS, Swain AF, Fry L, et al. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984;11:555-64.
3. Bos JD. The pathomechanisms of psoriasis; the skin immune system and cyclosporine. Br J Dermatol 1988;118:141-55.
4. De Rie MA, Hamerlinck F, Hintzen RQ, et al. Quantitation of soluble CD27, a T-cell activation antigen, and soluble interleukin-2 receptor in serum from patients with psoriasis. Arch Dermatol Res 1991;283:533-4.
5. Schopf RE, Höcher J, Schütz N, et al. Psoriasis treatment with etretinate versus cyclosporin A. Clinical course and serum concentrations of soluble interleukin-2 receptors and CD8 antigen. Eur J Dermatol 1992;2:224-30.
6. De Rie MA, Zonneveld IM, Witkamp W, et al. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. Acta Derm Venereol (Stockh) 1996;76:357-60.
7. Lee RE, Gaspari AA, Lotze MT, et al. Interleukin 2 and psoriasis. Arch Dermatol 1988;124:1811-5.
8. Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993;14:290-5.
9. Weinshenker BG, Bass BH, Ebers GC, et al. Remission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatment. J Am Acad Dermatol 1989;20:1132-3.
10. Nicolas J-F, Chamchick N, Thivolet J, et al. CD4 antibody treatment of severe psoriasis [letter]. Lancet 1991;338:321.
11. Jeffes EWB, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxix and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995;104:183-8.
12. Müller W, Herrmann B. Cyclosporin A for psoriasis [correspondence]. N Engl J Med 1979;301:555.
13. Van Hoof J, Leunissen K, Van der Staak W. Cyclosporin and psoriasis [letter]. Lancet 1985;i:335.
14. Mihatsch M, Wolff K. Consensus conference on cyclosporin for psoriasis. Br J Dermatol 1992;126:621-3.
15. Hiestand PC, Graber M, Hurtenbach U, et al. The new cyclosporin derivative SDZ Imm 125: in vitro and in vivo pharmacologie effects. Transplant Proc 1992;24(Suppl 2): 31-8.
16. Witkamp L, Zonneveld IM, Jung EG, et al. Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis. Br J Dermatol 1995;133:95-103.
17. De Rie MA, Meinardi MMHM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol (Stockh) 1991,71:452-4.
18. Powles AV, Baker BS, McFadden J, et al. Intralesional injection of cyclosporin in psoriasis. Lancet 1988;i:537.
19. Borel JF. Mechanism of action and rationale for cyclosporin A in psoriasis. Br J Dermatol 1990;122(Suppl 36):5-12.
20. Wong RL, Winslow CM, Cooper KD. The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993;14:69-73.
21. Mihatsch MJ, Thiel G, Ryffel B. Renal side-effects of cyclosporin A with special reference to autoimmune diseases. Br J Dermatol 1990;122(S36):101-5.
22. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992;13:136-42.
23. Meinardi MMHM, Bos JD. Immunopharmacological properties of ciclosporin in psoriasis. In: Van Joost T, Heule F, Bos JD, editors. Ciclosporin (Sandimmune®) in psoriasis. Alphen aan den Rijn: Samson Stafleu, 1988:26-49.
24. Müller EA, Kovarik JM, Van Bree JB. Pharmacokinetics and tolerability of a microeumulsion of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994;57:1178-82.
25. Johnston A. The relationship between Neoral® pharmacokinetics and meaningful clinical benefits. Proceedings of the International Congress on Immunointervention: The role of Neoral® in immune-based diseases; 1996 June 20-22; Rome, Italy. 1996:22-3.
26. Elder CA, Moore M, Chang C-T, et al. Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J Clin Pharmacol 1995;35:865-75.
27. Bourke JF, Berth-Jones J, Holder J, et al. New galenical formulation of cyclosporin (Neoral®) effective in the treatment of cyclosporin resistant dermatoses. Br J Dermatol 1995;133(Suppl 45):37.
28. Bos JD, Meinardi MMHM, Van Joost Th, et al. Use of cyclosporin in psoriasis. Lancet 1989;30:1500-2.
29. Meinardi MMHM, De Rie MA, Bos JD. Oral cyclosporin A in the treatment of psoriasis: an overview of studies performed in The Netherlands. Br J Dermatol 1990;122(Suppl 36):27-31.
30. Schulze H-J. Parallelgruppenvergelich von Sandimmun und etretinat bei Psoriasis vulgaris. Z Hautkr 1991;66(Suppl):33-8.
31. Laburte C, Grossman R, Abi-Rached J, et al. Efficacy and safety of oral cyclosporin (CyA; Sandimmun®) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994;130:366-75.
32. Zachariae H, Steen Olsen T. Efficacy of cyclosporin A (CyA) in psoriasis: An overview of dose/response, indications, contraindications and side-effects. Clin Nephrol 1995;43:154-8.
33. Witkamp L, Spuls PI, Bossuyt PMM, et al. A systematic review of five systemic treatments for severe psoriasis (submitted).
34. Timonen P, Friend D, Abeywickrama K, et al. Efficacy of low-dose cyclosporin A in psoriasis: results of dosefinding studies. Br J Dermatol 1990;122(Suppl 36):33-40.
35. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporin for plaque-type psoriasis: results of a multidose, double-blind trial. N Engl J Dermatol 1991;324:277-84.
36. Christophers E, Mrowietz U, Henneicke H-H, et al. Cyclosporine in psoriasis: a multi-center dose-finding study in severe plaque psoriasis. J Am Acad Dermatol 1992;26:86-90.
37. Powles AV, Baker BS, Valdimarsson H, et al. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol 1990;122(Suppl 36):13-20.
38. Ellis CN, Fradin MS, Hamilton TA, et al. Duration of remission during maintenance cyclosporin therapy for psoriasis: relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995;131:791-5.
39. De Rie MA, Meinardi MMHM, Bos JD. Analysis of sideeffects of medium- and low-dose cyclosporin maintenance therapy in psoriasis. Br J Dermatol 1990;123:347-53.
40. Grossman RM, Chevret S, Abi-Rached J, et al. Long-term safety of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996;132:623-9.
41. Mrowietz U, Farber L, Henneicke-von Zepelin H-H, et al. Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. J Am Acad Dermatol 1995;33:470-5.
42. Salomon D, Mesheit J, Masgrau-Peya E, et al. Acitretin does not prevent psoriasis relapse related to cyclosporin A tapering. Br J Dermatol 1994;130:257-8.
43. Mason J. Renal side-effects of cyclosporin A. Br J Dermatol 1990;122(Suppl 36):71-7.
44. Young EW, Ellis CN, Messana JM, et al. A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994;46:1216-22.
45. Feutren G, Abeywickrama K, Friend D, et al. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990; 122(Suppl 36):57-69.
46. Miyhatsch MJ, Antonovych T, Bohman S-O, et al. Cyclosporin A nephropathy: standardization of the evaluation of kidney biopsies. Clin Nephrol 1994;41:23-32.
47. Feutren G, Mihatsch M, and the International Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.
48. Cockburn IRT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989;2:723-31.
49. Matter BE, Donatsch P, Racine RR, et al. Genotoxicity evaluation of cyclosporin A, a new immunosuppressive agent. Mutat Res 1982;105:257-64.
50. Krupp P, Monka C. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol 1990;122(Suppl 36):47-56.
51. Perm I. Malignancy after immunosuppressive therapy. Clin Immunother 1995;4:207-18.
52. Gupta AK, Matterson EL, Ellis CN, et al. Cyclosporin in the treatment of psoriatic arthritis. Ann Rheum Dis 1989; 125:507-10.
53. Sandoz. The role of Neoral® in immune-based diseases. Abstracts of the International Congress on Immunointervention; 1996 June 20-22; Rome, Italy. London: Blackwell Healthcare Communications, 1996.
54. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy J Am Acad Dermatol 1993;28:454-9.
55. Griffiths CEM, Powles AV, Baker BS, et al. Combination of cyclosporin A and topical corticosteroid in the treatment of psoriasis. Transplantat Proc 1988;20(Suppl 4):50-2.
56. Grossman R, Thivolet J, Claudy A, et al. A novel therapeutic approach to psoriasis: combination calcipotriol ointment and very low dose cyclosporine-results of an multicenter placebo controlled study. J Am Acad Dermatol 1994;31:68-74.
57. Kino T, Hatanaka H, Hashimoto M, et ai. Prograt, a novel immunosuppressant isolated from Streptomyces. 1: Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-55.
58. MacLoad AM, Thompson AW. FK506: an immunosuppressant for the 1990s? Lancet 1991;337:25-7.
59. Abu-Elmagd K, Van Thiel D, Jegasothy BV, et al. FK506: a new therapeutic agent for severe recalcitrant psoriasisTransplant Proc 1991;23:3322-4.
60. The European FK 506 Multicentre Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind placebo-controlled study. Arch Dermatol 1996;132:419-23.
61. Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992;98:851-5.
62. Aoyama H, Tabata N, Tanaka M, et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment [correspondence]. Br J Dermatol 1995;133:492-500.
63. Lauerma AI, Maibach H, Granlund H, et al. Inhibition of contact allergy reactions by topical FK506 [letter]. Lancet 1992;340:556.
64. Grassberger MA, Baumann K. Macrolide immunosuppressants. Curr Opin Ther Patents 1993:931-49.
65. Rappersberger K, Meingasser JG, Fialla R, et al. Clearing of psoriasis by a novel immunosuppressive macrolide J Invest Dermatol 1996;106:701-10.
66. Vezina C, Kudelski A, Sehgal S. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the produc ing streptomycete and isolation of the active principle. J Antibiot 1975;28:721-6.
67. Kimball PM, Kerman RH, Kahan BD. Production of synergistic but non-identical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991;51:486-90.
68. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by Unrelated macrolides FK-506 and rapamycin. J Immunol 1990;144:251-8.
69. Bach J-F, Fracchia GN, Chatenoud L. Safety and efficacy of therapeutic monoclonal antibodies in clinical therapy Immunol Today 1993;14:421-5.
70. Rietmüller G, Rieber EP, Kiefersauers, et al. From anti-lymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 1992;129:81-104.
71. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis [letter]. Lancet 1991;338:320-1.
72. Princ JZ, Meurer M, Reiter C, et al. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412. J Am Acad Dermatol 1996;34:244-52.
73. Van der Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric CD4 monoclonal antibody cM-T412 as a therapeutic approach to rheumatoid arthritis. Arthritis Rheum 1993;36:1375-9.
74. Burrows NP, Isaacs JD, Norris PG, et al. Humanised monoclonal anti-CD4 therapy for psoriasis [abstract]. Br J Dermatol 1994;131(Suppl 44):17.
75. Craeven PJ, Stoll HL. Response to tumor necrosis factor in two cases of psoriasis. J Am Acad Dermatol 1991;24:735-7.
76. Takematsu H, Ozawa H, Yoshimura T, et al. Systemic TNF administration in psoriatic patients: a promising therapeutic modality for severe psoriasis [letter]. Br J Dermatol 1991;124:209-10.
77. Takematsu H, Ohta H, Tagami H. Absence of tumor necrosis factor-a in suction blister fluids and stratum corneum from patients with psoriasis. Arch Dermatol Res 1989;281:398-400.
78. Bos JD, Hulsebosch HJ, Krieg SR, et al. Irnmunocompetent cells in psoriasis; in situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983;275:181-9.
79. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med 1995;1:442-7.
80. Wetterberg L, Alexius B, Saaf J, et al. Peptide T in treatment of AIDS. Lancet 1987;i:159.
81. Marcusson JA, Talme T, Wetterberg L, et al. Peptide T a new treatment for psoriasis? A study of nine patients. Acta Derm Venereol (Stockh) 1991;71:479-83.
82. Delfino M, Fabbrocini G, Brunetti B, et al. Peptide T in the treatment of severe psoriasis. Acta Derm Venereol (Stockh) 1992;72:68-9.
83. Farber EM, Cohen EN, Wilkinson DI. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermat 1991;25:658-64.
84. Ahmed AR, Moy R. Azathioprine. Int J Dermatol 1981;20:461-7.
85. Younger IR, Harris DWS, Colver GB. Azathioprine in dermatology. J Am Acad Dermatol 1991;25:281-6.
86. Du Vivier, Monro D, Verbov J. Treatment of psoriasis with azathioprine. Br Med J 1974;1:49-51.
87. Zackheim HS, Glogau RG, Fisher DA, et al. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol 1994;30:452-8.
88. Gasparro F, Edelson RL. Extracorporeal photochemotherapy. In: Krutmann J, Elmets CA, editors. Photoimmunology. Oxford: Blackwell Science, 1995:231-45.
89. Vowels BR, Cassin M, Boufal MH, et al. Extracorporeal photochemotherapy induces the production of tumor necrosis factor alfa by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992;98:686-92.
90. Wilfert H, Hönigsmann H, Steiner G, et al. Treatment of psoriasis arthritis by extracorporeal photochemotherapy. Br J Dermatol 1990;122:225-32.
91. De Misa RF, Azana JM, Harto A, et al. Psoriatic arthritis: one year of treatment with extracorporeal photochemotherapy. J Am Acad Dermatol 1994;30:1037-8.
92. Reitamo S, Mustakallio KK. Cyclosporin in erythrodermic psoriasis. Acta Derm Venereol Suppl (Stockh) 1989;146:140-1.
93. Cimitan A, Fantini F, Gianetti A. Clinical trial with cyclosporin A. Acta Derm Venereol Suppl (Stockh) 1989;146:159-63.
94. Bonifati C, Clerico R, Potenza CM, et al. Cyclosporin A, preliminary results in the treatment of psoriasis. Acta Derm Venereol Suppl (Stockh) 1989;146:151-4.
95. Fradin MS, Ellis CN, Voorhees JJ. Efficacy of Cyclosporin A in psoriasis: a summary of the United States' experience. Br J Dermatol 1990;122(Suppl 36):21-5.
96. Korstanje MJ, Bessems PJMJ, Hulsmans RFHJ, et al. Pustular psoriasis and acrodermatitis continua (Hallopeau) need high doses of systemic ciclosporin A [letter]. Dermatologica 1989;179:90-1.
97. Meinardi MMHM, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987;116:269-70.
98. Meinardi MMHM, De Rie MA, Bos JD. Oral Cyclosporin A is effective in clearing persistent pustulosis palmaris et plantaris. Acta Derm Venereol (Stockh) 1990;70:77-9.
99. Reitamo S, Erkko P, Remitz A, et al. Cyclosporin in the treatment of palmoplantar pustulosis. Arch Dermatol 1993;129:1273-9.
100. Peter RU, Färber L, Weiss J, et al. Low-dose cyclosporin A in palmoplantar psoriasis: evaluation of efficacy and safety. J Eur Acad Dermatol Venereol 1994;3:518-24.
101. Doyle DV, Huskisson EC, Greenwood A, et al. Psoriatic arthritis: a placebo controlled study of treatment with cyclosporin A and azathioprine. Br J Rheumatol 1989;28(Suppl 1):53.
102. Steinsson K, Jónsdóttir I, Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990;49:603-6.
103. Mahrle G, Schulze H-J, Färber L, et al. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88.
104. Riccieri V, Sili-Scavalli A, Spadaro A, et al. Short-term 'Cyclosporin A' therapy for psoriatic arthritis. Acta Derm Venereol Suppl (Stockh) 1994;186:94-5.
105. Schopf RE, Bräutigam M, Morsches B. Cyclosporin A benefits both skin and joint diseases in psoriatic arthritis. J Invest Dermatol 1994;102:616.
106. Tosti A, Guerra L, Bardazzi F, Lanzarini M. Topical ciclosporin in nail psoriasis. Dermatologica 1990;180:110-2.